This activation enhanced antigen presentation to CD8+ T lymphocytes, ultimately reducing tumor growth (CT26 colon carcinoma, Lewis lung carcinoma, and Hca-f hepatocarcinoma) across three distinct murine models (BALB/c, C57BL/6, and C3H/He). Here, CD8A is linked to colon carcinoma.